These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 14745692)

  • 1. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
    Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
    J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues.
    Watanabe M; Igai K; Matsuoka K; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
    Infect Immun; 2006 Mar; 74(3):1984-8. PubMed ID: 16495579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
    Nishikawa K; Matsuoka K; Kita E; Okabe N; Mizuguchi M; Hino K; Miyazawa S; Yamasaki C; Aoki J; Takashima S; Yamakawa Y; Nishijima M; Terunuma D; Kuzuhara H; Natori Y
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7669-74. PubMed ID: 12032341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and assessment of globotriose-chitosan conjugate, a novel inhibitor of shiga toxins produced by Escherichia coli.
    Li X; Wu P; Cheng S; Lv X
    J Med Chem; 2012 Mar; 55(6):2702-10. PubMed ID: 22372889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
    Nishikawa K
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):239-47. PubMed ID: 21644029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
    Karmali MA
    J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli.
    Paton JC; Rogers TJ; Morona R; Paton AW
    Infect Immun; 2001 Mar; 69(3):1389-93. PubMed ID: 11179303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drugs that prevent cytotoxicity of Shiga toxins].
    Natori Y
    Nihon Rinsho; 2002 Jun; 60(6):1131-7. PubMed ID: 12078085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escherichia coli O157:H7 and non-O157 Shiga toxin-producing E. coli in healthy cattle, sheep and swine herds in Northern Spain.
    Oporto B; Esteban JI; Aduriz G; Juste RA; Hurtado A
    Zoonoses Public Health; 2008; 55(2):73-81. PubMed ID: 18234025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission].
    Rivas M; Miliwebsky E; Chinen I; Deza N; Leotta GA
    Medicina (B Aires); 2006; 66 Suppl 3():27-32. PubMed ID: 17354474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.
    Mulvey GL; Marcato P; Kitov PI; Sadowska J; Bundle DR; Armstrong GD
    J Infect Dis; 2003 Feb; 187(4):640-9. PubMed ID: 12599081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli.
    Cilmi SA; Karalius BJ; Choy W; Smith RN; Butterton JR
    J Infect Dis; 2006 Oct; 194(8):1135-40. PubMed ID: 16991089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Gb3 in lipid rafts in resistance to Shiga-like toxin of mutant Vero cells.
    Hanashima T; Miyake M; Yahiro K; Iwamaru Y; Ando A; Morinaga N; Noda M
    Microb Pathog; 2008 Aug; 45(2):124-33. PubMed ID: 18541402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
    Okayama A; Mikasa K; Matsui N; Higashi N; Miyamoto M; Kita E
    J Infect Dis; 2004 Dec; 190(12):2129-36. PubMed ID: 15551211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.
    Müthing J; Schweppe CH; Karch H; Friedrich AW
    Thromb Haemost; 2009 Feb; 101(2):252-64. PubMed ID: 19190807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine immune response to shiga-toxigenic Escherichia coli O157:H7.
    Hoffman MA; Menge C; Casey TA; Laegreid W; Bosworth BT; Dean-Nystrom EA
    Clin Vaccine Immunol; 2006 Dec; 13(12):1322-7. PubMed ID: 17050743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose.
    Paton AW; Morona R; Paton JC
    Infect Immun; 2001 Mar; 69(3):1967-70. PubMed ID: 11179385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins.
    Neri P; Nagano SI; Yokoyama S; Dohi H; Kobayashi K; Miura T; Inazu T; Sugiyama T; Nishida Y; Mori H
    Microbiol Immunol; 2007; 51(6):581-92. PubMed ID: 17579269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotypes and virulence markers of Shiga toxin-producing Escherichia coli (STEC) isolated from dairy cattle in São Paulo State, Brazil.
    Irino K; Kato MA; Vaz TM; Ramos II; Souza MA; Cruz AS; Gomes TA; Vieira MA; Guth BE
    Vet Microbiol; 2005 Jan; 105(1):29-36. PubMed ID: 15607081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shiga toxin mode of action in E. coli O157:H7 disease.
    Obrig TG
    Front Biosci; 1997 Dec; 2():d635-42. PubMed ID: 9392626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.